NCT04789655CompletedPhase 1
A Dose Finding Phase 1 Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Feb 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 21 Sept 2022
- Start date
- 6 Jul 2021
- Lead sponsor
- Celgene Corp.
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT04789655
- EU CT number
- 2022-500573-13-00
- EudraCT number
- 2020-003782-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 22
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Completed |
| Hopital Saint Louis Coordinator of this site? Confirm its status | Paris | France | Completed |
| Centre Hospitalier Universitaire de Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.